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Objectives: To assess the clinical use of panfungal PCR for diagnosis of invasive fungal diseases (IFDs). We
focused on the deep tissue samples.
Methods: We ﬁrst described the design of panfungal PCR, which is in clinical use at Helsinki University
Hospital. Next we retrospectively evaluated the results of 307 fungal PCR tests performed from 2013 to
2015. Samples were taken from normally sterile tissues and ﬂuids. The patient population was nonse-
lected. We classiﬁed the likelihood of IFD according to the criteria of the European Organization for
Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG), comparing the fungal
PCR results to the likelihood of IFD along with culture and microscopy results.
Results: There were 48 positive (16%) and 259 negative (84%) PCR results. The sensitivity and speciﬁcity
of PCR for diagnosing IFDs were 60.5% and 91.7%, respectively, while the negative predictive value and
positive predictive value were 93.4% and 54.2%, respectively. The concordance between the PCR and the
culture results was 86% and 87% between PCR and microscopy, respectively. Of the 48 patients with
positive PCR results, 23 had a proven or probable IFD.
Conclusions: Fungal PCR can be useful for diagnosing IFDs in deep tissue samples. It is beneﬁcial to
combine fungal PCR with culture and microscopy. M. Ala-Houhala, Clin Microbiol Infect 2018;24:301
© 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.Introduction
Invasive fungal diseases (IFDs) are an emerging clinical dilemma
in critically ill patients. The number of patients in an immuno-
suppressive state (e.g. due to cancer, transplantation, HIV or the use
of immunosuppressive agents) has risen substantially in the last
few years. Invasive candidiasis and invasive aspergillosis are the
most common IFDs diagnosed in immunocompromised patients
[1e4]. However, the epidemiology of IFDs has changed in recent
years; Candida species are still one of the most frequent causes of
IFDs, but the incidence of Aspergillus species and other ﬁlamentous
fungi, such as Zygomycetes, Fusarium and Scedosporium spp., hasCenter, Division of Infectious
of Helsinki, Finland.
tila).
biology and Infectious Diseases. Puincreased [2,5e9]. IFDs are difﬁcult to treat, and they place a
remarkable ﬁnancial burden on the healthcare system [10e12].
The diagnosis of IFD is challenging. Clinical manifestations are
often nonspeciﬁc and mild in the early phase of infection. Standard
methods of diagnosis, microscopy and culture lack efﬁciency and
have a low sensitivity [13,14]. Microscopic identiﬁcation requires
skilled personnel, and it is demanding to differentiate, for example,
Aspergillus hyphae from those of Fusarium and Scedosporium spp.
However, a speciﬁc identiﬁcation of the infecting species would be
important for implementation of an appropriate antifungal therapy.
Molecular-based methods like PCR-based techniques can poten-
tially offer a more rapid diagnosis [14e17]. PCR assays usually have
a higher sensitivity than conventional methods, and they allow
detection of a small amount of DNA [15,18]. Species-speciﬁc
designed PCR can be fast and sensitive for diagnosing fungal dis-
ease [19], but panfungal techniques cover potentially the range of
fungi causing IFDs. Only a few commercial methods are available;blished by Elsevier Ltd. All rights reserved.
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rapid development of sequencing technologies might change
fungal diagnostics in the future [21].
Here we describe the design of a panfungal PCR. We compare
the PCR results to the culture and microscopy results as well as
evaluate the clinical use of panfungal PCR for diagnosing IFDs.
Materials and Methods
The panfungal PCR described here is in clinical use at Helsinki
University Hospital Laboratory (HUSLAB). We investigated the
clinical use of this fungal PCR for diagnosing IFDs in southern
Finland from 2013 to 2015. The analysis is retrospective and
observational. We focused on PCR samples taken from deep tissues
and ﬂuids. Blood and bronchoalveolar lavage ﬂuid samples were
excluded from this study.
Design of fungal PCR
The PCR was designed to identify ribosomal DNA sequences of
fungal chromosomes. The primers were designed with Allele ID and
Beacon Designer software (Palo Alto, CA, US) to recognize two target
gene regions, using the Basic Local Alignment Search Tool (BLAST;
National Center for Biotechnology Information, Bethesda, MD, USA;
https://blast.ncbi.nlm.nih.gov/Blast.cgi) for searching its database to
predict secondary structures. The forward primer oligonucleotide
sequence for its_03 was GCATATCAATAAGCGGAGGA, and the
reverse primerwas CAGGCATAGTTCACCATCT, both ofwhich amplify
fungal 28S rRNA sequence (788 bp). For its_05, the forward primer
was GATTGAATGGCTTAGTGAGG, and the reverse primer was
TTGTTCGCTATCGGTCTC, and they amplify approximately 1000 bp
sequences starting from the end of 18S sequence.
PCR was performed using the DNA Engine Tetrad 2 Peltier
Thermal Cycler (Bio-Rad, Hercules, CA, USA), and thermocycling
was carried out under the following conditions: initial denaturation
and activation at 95C for 15 minutes, 40 cycles of denaturation at
94C for 20 seconds, annealing at 60C for 70 seconds and exten-
sion at 72C for 1 minute. The 20 mL reaction contained 0.1 mL
Qiagen HotstarTaq (Qiagen, Venlo, the Netherlands), 0.2 mM dNTP,
0.5 mM primers and 5 mL template DNA. PCR-ampliﬁed fragments
were separated using agarose gel electrophoresis and visualized
under ultraviolet light. Ampliﬁed fragments were puriﬁed with
ExoSAP Cleanup Reagent (Thermo Fisher Scientiﬁc, Waltham, MA,
USA) and sequenced with a BigDye Terminator v3.1 Cycle
Sequencing Kit (Thermo Fisher Scientiﬁc) using both the forward
and reverse primers and an ABI Prism 3100 genetic analyzer
(Thermo Fisher Scientiﬁc). Then analysis was performed by BLAST.
An inhibition control (ampliﬁcation of lambda DNA or Oryza sativa
gene) was tested with each sample, a nontemplate control was
tested with each run and the extraction control was tested with
each extraction lot. In addition, with each sample, an empty
reference container, opened in the sampling site, was used as a
negative control.
Fungal strains and clinical samples
The clinical samples were cultured by routine diagnostics at
HUSLAB using standard methods [22,23].
For the PCR analyses, fungus cells were collected in 650 mL
of water and homogenized in Precellys (Bertin Instruments,
Montigny-le-Bretonneux, France), and 100 mL of the homogenized
mixture was puriﬁed with the NucliSENS kit (bioMerieux, Marcy
l’Etoile, France) using the easyMAG automatic nucleic acid puriﬁ-
cation platform (bioMerieux), as described by the manufacturer.
DNA was eluted to 100 mL, of which 1 mL was directly used for PCRampliﬁcation. The clinical samples (tissue samples were approxi-
mately 3  3 mm and ﬂuid samples were >0.2 mL) were homog-
enized in Precellys solution and puriﬁed using the Nordiag Arrow
instrument (Isogen Life Science, Utrecht, the Netherlands) with a
Viral NA Kit (DiaSorin, Saluggia, Italy) before PCR analysis. All
clinical samples were fresh and were stored, if necessary, for a
maximum of 4 days at þ4C before analysis.
For medical record review, patients were retrospectively iden-
tiﬁed from the microbiologic laboratory database at Helsinki Uni-
versity Hospital. The patient population was nonselected. We
reviewed the medical records of all patients whose samples un-
derwent a fungal PCR as part of their clinical care from 1 January
2013 to 31 December 2015. Culture and microscopy were per-
formed on the same sample as fungal PCR. We included tissue and
ﬂuid specimens taken from normally sterile body sites (e.g. cere-
brospinal ﬂuid, pleural effusion, ascites, vitreous body, liver, lung,
lymph node, bone). We excluded bronchoalveolar lavage and blood
samples from the analysis.
Patient charts were reviewed, and we collected data related to a
possible IFD (e.g. age, gender, immunosuppressive state, comor-
bidities, primary site of the sample, culture and microscopy results,
primary antifungal therapy). Patients were considered to be in an
immunosuppressive state when they had haematologic malig-
nancy, HIV, genetic immunodeﬁciency and active cancer for which
they had received chemotherapy during the past 30 days; and a
history of solid organ transplantation, hematopoietic stem cell
transplantation or immunosuppressive medication. Immunosup-
pressive medications included prednisolone (15 mg per day taken
for more than 3 weeks), biological drugs, cyclosporine, tacrolimus
mycophenolate, azathioprine and methotrexate. We classiﬁed the
likelihood of a fungal infection according to the criteria of European
Organization for Research and Treatment of Cancer/Invasive Fungal
Infections Cooperative Group and the National Institute of Allergy
and Infectious Diseases Mycoses Study Group (EORTC/MSG) [24].
We compared the standard diagnostic methods of culture and
microscopy to the PCR results.
The study protocol was approved by the research board of the
Inﬂammation Center at the Helsinki University Hospital.
Statistical analysis
Statistical analyses were carried out by SPSS Statistics 22 (IBM
SPSS, Chicago, IL, USA). The sensitivity, speciﬁcity, positive pre-
dictive value (PPV) and negative predictive value (NPV) were
identiﬁed.
Results
Design and validation of fungal PCR
The PCR method was designed to identify (its) regions of the
fungal ribosomal gene. The primers were designed to identify all
fungus species but not to bind human or bacterial DNA. The PCR
assay was optimized and validated using reference strains,
including 30 fungal pathogens and two bacteria strains
(Supplementary Table 1). All positive control strains were correctly
identiﬁed, with no false-positive ampliﬁcations. All strains were
ampliﬁed with both primer pairs (its_03 and its_05), except
Rhizopus oryzae and Scopulariopsis brevicaulis, which were only
positive with the its_05 primers (Supplementary Table 1). Upon
sequence analysis, all strains had more than 99% homology with
the correct target. Thus, the assay attained 100% analytic speci-
ﬁcity. The analytic sensitivity of the PCR was deﬁned by tenfold
dilutions of the template DNA of Candida albicans. The sensitivity
with 40 ampliﬁcation cycles was 100 fg/mL, which corresponds to
Table 2
Comparison of PCR results with culture and microscopy ﬁndings
Mode Finding PCR result, n (%)
Positive Negative
Culturea Positive 12 (4) 9 (3)
Negative 34 (11) 248 (82)
Microscopyb Positive 16 (5) 8 (3)
Negative 31 (10) 247 (82)
Culture þ microscopy Both positive 10 (3) 3 (1)
One positive 9 (3) 11 (4)
Both negative 29 (9) 245 (80)
a Culture results were missing for four patients (two PCR positive, two PCR
negative).
b Microscopy results were missing for ﬁve patients (one PCR positive, four PCR
negative).
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detected in the clinical samples.
Clinical analysis
In total, 632 PCR samples from a nonselected population were
obtained during the study period. We excluded 325 of these 632
samples when patient documentationwas unavailable or when the
material was not sampled from a sterile body site. The remaining
307 samples (n ¼ 296 patients) were enrolled onto the study.
Culture results were missing for four specimens and microscopy
results for ﬁve. The patients' median age was 54 years (range,
1e87 years). Twenty-ﬁve patients (8.1%) were younger than
18 years, and 182 of the patients were male (59.3%). In total, 127
patients (41%) were immunocompromised, 28 (9.1%) had received a
transplant and 57 (18.5%) were diagnosed with a haematologic
malignancy (Table 1).
Clinical sensitivity and speciﬁcity
Overall, there were 48 positive (16%) PCR results and 259
negative (84%) ones (Table 2). The culture was positive for 21 pa-
tients (7%) and negative for 282 (93%); microscopy was positive for
24 patients (8%) and negative for 278 (92%). The concordance rate
for the PCR and culture results was 86%, while it was 87% between
PCR and microscopy. The sensitivity of PCR compared to culture
was 57% and speciﬁcity was 88%. In contrast with microscopy, PCR
had a sensitivity of 65% and a speciﬁcity of 89%. There were nine
samples with a positive culture result but a negative PCR outcome.
Of these nine samples, culture identiﬁed Aspergillus fumigatus
(n ¼ 3), Candida albicans (n ¼ 5) and Candida glabrata (n ¼ 1). For
ﬁve of these samples, there was very little growth in the culture;
three of these patients did not have IFDs. For two of the nine
samples, the culture and PCR were probably performed using two
different tissue samples, which may explain the discordant results.
We calculated the sensitivity, speciﬁcity, NPV and PPV of fungal
PCR in relation to the likelihood of IFD using the EORTC criteria. The
sensitivity of PCR for diagnosing IFD was 60.5%; the speciﬁcity was
91.7%, and the NPV and PPV were 93.4% and 54.2%, respectively.
Twenty-two samples had positive PCR results even though
culture and microscopy results were negative and the patients did
not have an IFD. Most of these PCR results were due toTable 1
Demographic and clinical characteristics of 307 patients
Characteristic Variable Value
Gender Female 125 (40.7%)
Male 182 (59.3%)
Age Median years 54
0e17 years 25 (8.1%)
18e65 years 199 (64.8%)
>65 years 83 (27.0)
Three-month
mortality
Alive 284 (92.5%)
Dead 23 (7.5%)
Immunosuppression None 180 (58.6%)
Haematologic malignancy 57 (18.5%)
HIV 12 (3.9%)
Genetic immunodeﬁciency 4 (1.3%)
Active cancera treated
with chemotherapy
12 (3.9%)
Immunosuppressive
medication
14 (4.6%)
Type of transplant Solid organ 14 (4.6%)
Stem cell 14 (4.6%)
Transplantation Yes 28 (9.1%)
No 279 (90.9%)
a Other than haematologic malignancy.contaminants from skin, environment or laboratory procedure (e.g.
11Malassezia spp.) (Table 3). In 16 of the 22 samples, the PCR results
were positive, but the laboratory reported that these results were
very likely due to contamination from the skin or environment, a
hypothesis with which the clinician agreed.When these 16 samples
were excluded from the results, the speciﬁcity of fungal PCR for
diagnosing IFDs increased to 97.6%.
The sensitivity of culture for diagnosing IFDwas 43.9%, while the
speciﬁcity was 98.8%. Cultures had an NPV of 91.8% and a PPV of
85.7%. IFD could be diagnosed using microscopy with a sensitivity
of 50%, a speciﬁcity of 98.8% and NPV and PPV of 92.4% and 87.5%,
respectively.Specimens
The quality of the specimens is listed in Table 4. The most
frequent specimen sites were cerebrospinal ﬂuid (16%), soft tissue
abscess (13%) and lung tissue (12%). Lung samples were most
frequently positive on PCR. Therewere 12 positive (38%) PCR results
from lung samples and 15 proven or probable fungal infections.
Overall, 43 patients (14%) had IFDs, which were proven (n ¼ 29),
probable (n ¼ 10) and possible (n ¼ 4). Of these, 18 patients had a
haematologic malignancy, and seven had received a solid or stem-
cell transplant. PCR was positive in 23 (59%) of 39 cases, and these
patients were diagnosed with a proven or probable IFD.
There were 48 positive (16%) PCR results, and 23 of these had
proven or probable IFD. There was a positive correlation between
the PCR results and IFD diagnosis (proven/probable) (p < 0.001).
The species identiﬁed by PCR and diagnosed as proven or probableTable 3
Summary of specimens without clinical invasive fungal disease
identiﬁed by PCR (n ¼ 22)a
Species No.
Aspergillus fumigatus 1
Aspergillus versicolor 1
Aspergillus conigus 1
Candida albicans 2
Candida parapsilosis 1
Candida sake 1
Cryptococcus albidus 1
Cladosporium spp. 2
Malassezia spp. 11
Rhodotorula spp. 1
Total 22
a Fungus samples were tested according to European Organization
for Research and Treatment of Cancer/National Institute of Allergy
and Infectious Diseases Mycoses Study Group criteria. Findings were
negative in these specimens by both microscopy and culture.
Table 4
Findings of different clinical specimens
Site of specimen All, n (%) Positive PCR
specimen, n (%)
Proven or probable
invasive fungal
disease, n (%)a
Cerebrospinal ﬂuid 49 (16.0) 3 (6.1) 1 (2.0)
Soft tissue abscess 40 (13.0) 6 (15.0) 5 (12.5)
Lung 38 (12.4) 12 (31.6) 15 (39.5)
Pleural effusion 31 (10.1) 6 (19.4) 2 (6.5)
Liver 27 (8.8) 5 (18.5) 7 (25.9)
Bone 23 (7.5) 1 (4.3) 0 (0.0)
Vitreous body 16 (5.2) 2 (12.5) 3 (18.8)
Lymph node 15 (4.9) 2 (13.3) 0 (0.0)
Cerebral tissue 14 (4.6) 2 (14.3) 0 (0.0)
Other tissues 54 (17.6) 9 (16.7) 6 (11.1)
Total 307 (100.0) 48 (15.6) 39 (12.7)
a European Organization for Research and Treatment of Cancer/National Institute
of Allergy and Infectious Diseases Mycoses Study Group criteria.
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(n ¼ 7), Candida spp. (n ¼ 9), Rhizopus spp. (n ¼ 2), Hormographiella
aspergillata (n ¼ 1), Histoplasma capsulatum (n ¼ 1), Scedosporium
apiospermum (n ¼ 1), Phoma opuntiae (n ¼ 1) and Cryptococcus
albidus (n ¼ 1). Sixteen patients had a proven or probable IFD but a
negative fungal PCR result. These cases are summarized in
Supplementary Table 2.
Discussion
In the present study, we describe design of a fungal PCR and
evaluate the clinical performance of the PCR for diagnosing IFDs
using deep tissue and ﬂuid samples. Our results revealed the
concordance between PCR and the conventional methods of culture
and microscopy was >85%. In our study, fungal PCR identiﬁed
fungal pathogens in 23 (59%) of 39 cases with a proven or probable
IFD. The speciﬁcity of the fungal PCR compared to the likelihood of
a fungal infection was 91.7%.Table 5
Summary of PCR-positive samples with proven or probable invasive fungal diseases
Site of specimen Fungus species identiﬁed by PCR Fungus culture res
Lung Rhizopus microphorus Rhizopus micropho
Lung Hormographiella aspergillata Negative
Lung Aspergillus fumigatus A. fumigatus
Lung A. fumigatus A. fumigatus
Lung A. fumigatus Negative
Lung Histoplasma capsulatum Negative
Lung Rhizomucor spp. Negative
Lung A. fumigatus Missing
Pleural effusion Candida albicansb Negative
Liver C. albicans Negative
Liver Candida krusei C. krusei
Liver A. fumigatus A. fumigatus
Liver C. albicans/Candida glabrata C. albicans/C. glabr
Liver C. albicans Negative
Subcutis C. albicans C. albicans
Subcutis Phoma opuntiae P. opuntiae
Subcutis Scedosporium apiospermum S. apiospermum
Vitreous body Candida dubliniensis C. dubliniensis
Abscess Candida parapsilosis Pyrenochaeta rome
Maxillary cavity A. fumigatus A. fumigatus
Lung A. fumigatus Negative
Vitreous body C. albicans Negative
Bone marrow Cryptococcus albidus Negative
EORTC/MSG, European Organization for Research and Treatment of Cancer/National Inst
a PCR, culture and microscopy were performed on lung biopsy samples. Pathology w
nation of removed tissue.
b Lung transplantation. Patient had systemic candidiasis. Culture was positive, with C.
abscess. Sample for PCR assay was taken during later phase of infection. Culture and miSeveral studies have examined fungal PCR, mostly from blood
samples [25e28]. Our goal was to evaluate panfungal PCR from
deep tissue samples. The analytic speciﬁcity of the fungal PCR
described in this study was excellent, reaching 100%. Our study was
performed in a nonselected population. Lass-Fl€orl et al. [16] eval-
uated the use of broad-range PCR to diagnose fungal infections in
microscopy-negative samples. Their results showed higher ﬁgures
than our study; the sensitivity of the broad-range PCR for diagnosis
of IFDs was 95.6% and the speciﬁcity was 96.4%. They analysed their
patient population further than our study did and excluded any
patients unlikely to have a fungal infection. Trubiano et al. [29]
studied the use of panfungal PCR for sterile site specimens and
bronchoalveolar lavage specimens, demonstrating that panfungal
PCR outperformed culture and histopathology from tissue speci-
mens. Hammond et al. [30] studied the use of PCR in patients with
haematologic malignancy and also in hematopoietic stem-cell
transplant recipients with proven mucormycosis. They showed
that PCR is useful for conﬁrming the diagnosis of mucormycosis.
There were some limitations in our study. This was a single-
centre retrospective study. PCR samples were obtained during
routine clinical care when there was suspicion of a fungal infection.
However, in the end, the likelihood of fungal infectionwas very low
in many patients. Our study population included patients with
malignancy, vasculitis, bacterial infections and so on.
In our study, the sensitivity of PCR for diagnosing IFDs remained
fairly low (60.5%), even though it was higher than that of culture or
microscopy. The sensitivity might have been limited by the DNA
extraction method used in the study, which was chosen on the
basis of the very low background DNA in reagents and consumables
to increase speciﬁcity. Sensitivity might be theoretically better with
other methods. Developing better extraction chemistry should
improve clinical sensitivity in future.
Contaminants can affect the utility of fungal PCR. Twenty-two
samples (Table 3) had a positive PCR result in our study, but the
corresponding culture and microscopy were negative, and the pa-
tients did not have a clinical IFD. In these 22 samples, PCR identiﬁedult Fungus microscopy
result
Primary antifungal
treatment
EORTC/MSG
criteria
rus Negative Amphotericin B Proven
Hypha Amphotericin B Proven
Hypha Voriconazole Proven
Hypha Voriconazole Proven
Hypha Voriconazole Proven
Negative Noa Proven
Hypha Amphotericin B Proven
Hypha Voriconazole Proven
Negative Caspofungin Proven
Yeast Missing Proven
Yeast Anidulafungin Proven
Hypha Voriconazole Proven
ata Yeast Missing Proven
Yeast Caspofungin Proven
Yeast Caspofungin Proven
Missing No Proven
Hypha Voriconazole Proven
Negative Fluconazole Proven
roi Negative Voriconazole Proven
Hypha Voriconazole Proven
Negative Caspofungin Probable
Negative Fluconazole Probable
Negative Fluconazole Probable
itute of Allergy and Infectious Diseases Mycoses Study Group.
as treated by surgical removal. Diagnosis was conﬁrmed by histopathologic exami-
albicans identiﬁed in samples taken from blood, pleural effusion and subcutaneous
croscopy were negative when performed on same sample as PCR.
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patient's skin or the laboratory procedure. PCR also identiﬁed Cla-
dosporium spp. (n ¼ 2), Cryptosporidium albidus (n ¼ 1), Aspergillus
versicolor (n ¼ 1) and Aspergillus conigus (n ¼ 1), which were most
likely contaminations from the environment. There were two cases
in which PCR assay had a very weak, uncertain positive result,
identifying Aspergillus fumigatus and Candida albicans. Culture and
microscopy were negative in both cases. The ﬁrst patient had a
mycobacterial infection in his lungs and the other had an oeso-
phageal carcinoma. One patient had an abscess in the subman-
dibular area caused by Staphylococcus aureus, but the fungal PCR
identiﬁed Candida albicans. The PCR result might have been a
contamination from oral mucosa. In one case, PCR assay identiﬁed
Rhodotorula spp. in a soft tissue abscess with sepsis caused by
Fusobacterium nucleatum. However, the PCR sample was taken
inadequately, which may have inﬂuenced the result. In two cases
PCR identiﬁed Candida spp., but neither patient had a clinical fungal
infection. A cerebrospinal ﬂuid sample from the ﬁrst patient
revealed Candida sake, and a brain biopsy sample of the other
revealed Candida parapsilosis.
In conclusion, the analytic speciﬁcity of the fungal PCR
described in our study was excellent (100%). According to the
EORTC criteria, the speciﬁcity of fungal PCR compared to the like-
lihood of IFD was 91.7%. Fungal PCR is a useful tool for the diagnosis
of IFDs in conjunction with culture and microscopy from deep tis-
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